Literature DB >> 23359572

Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.

Srinath Kasturirangan1, Tim Reasoner, Philip Schulz, Shanta Boddapati, Sharareh Emadi, Jon Valla, Michael R Sierks.   

Abstract

We developed atomic force microscope (AFM)-based protocols that enable isolation and characterization of antibody-based reagents that selectively bind target protein variants using low nanogram amounts or less of unpurified starting material. We isolated single-chain antibody fragments (scFvs) that specifically recognize an oligomeric beta-amyloid (Aβ) species correlated with Alzheimer's disease (AD) using only a few nanograms of an enriched but not purified sample obtained from human AD brain tissue. We used several subtractive panning steps to remove all phage binding nondesired antigens and then used a single positive panning step using minimal antigen. We also used AFM to characterize the specificity of the isolated clones, again using minimal material, selecting the C6 scFv based on expression levels. We show that C6 selectively binds cell and brain-derived oligomeric Aβ. The protocols described are readily adapted to isolating antibody-based reagents against other antigenic targets with limited availability.
Copyright © 2013 American Institute of Chemical Engineers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359572      PMCID: PMC3618510          DOI: 10.1002/btpr.1698

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  32 in total

1.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 2.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

3.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

Review 4.  Mechanisms of neuronal degeneration in Alzheimer's disease.

Authors:  B A Yankner
Journal:  Neuron       Date:  1996-05       Impact factor: 17.173

5.  Alzheimer's drugs take a new tack.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

6.  Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens.

Authors:  M D Sheets; P Amersdorfer; R Finnern; P Sargent; E Lindquist; R Schier; G Hemingsen; C Wong; J C Gerhart; J D Marks; E Lindqvist
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

8.  Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.

Authors:  J D Harper; S S Wong; C M Lieber; P T Lansbury
Journal:  Chem Biol       Date:  1997-02

9.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

10.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

Authors:  J D Marks; H R Hoogenboom; T P Bonnert; J McCafferty; A D Griffiths; G Winter
Journal:  J Mol Biol       Date:  1991-12-05       Impact factor: 5.469

View more
  15 in total

1.  Bispecific Antibody Fragment Targeting APP and Inducing α-Site Cleavage Restores Neuronal Health in an Alzheimer's Mouse Model.

Authors:  Ping He; Wei Xin; Philip Schulz; Michael R Sierks
Journal:  Mol Neurobiol       Date:  2019-04-30       Impact factor: 5.590

2.  CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury.

Authors:  Stephanie M Williams; Carrie Peltz; Kristine Yaffe; Philip Schulz; Michael R Sierks
Journal:  Neurology       Date:  2018-10-09       Impact factor: 9.910

3.  Isolation and characterization of antibody fragment selective for human Alzheimer's disease brain-derived tau variants.

Authors:  Lalitha Venkataraman; Ping He; Philip Schulz; Michael R Sierks
Journal:  Neurobiol Aging       Date:  2020-04-24       Impact factor: 4.673

4.  Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis.

Authors:  Stephanie M Williams; Lalitha Venkataraman; Huilai Tian; Galam Khan; Brent T Harris; Michael R Sierks
Journal:  J Vis Exp       Date:  2015-02-12       Impact factor: 1.355

Review 5.  APP/Aβ structural diversity and Alzheimer's disease pathogenesis.

Authors:  Alex E Roher; Tyler A Kokjohn; Steven G Clarke; Michael R Sierks; Chera L Maarouf; Geidy E Serrano; Marwan S Sabbagh; Thomas G Beach
Journal:  Neurochem Int       Date:  2017-08-12       Impact factor: 3.921

6.  Isolation and characterization of antibody fragments selective for toxic oligomeric tau.

Authors:  Huilai Tian; Eliot Davidowitz; Patricia Lopez; Ping He; Philip Schulz; James Moe; Michael R Sierks
Journal:  Neurobiol Aging       Date:  2014-12-11       Impact factor: 4.673

7.  Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Authors:  Stephanie M Williams; Philip Schulz; Michael R Sierks
Journal:  Eur J Neurosci       Date:  2015-10-15       Impact factor: 3.386

8.  A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers.

Authors:  Adriano Sebollela; Erika N Cline; Izolda Popova; Kevin Luo; Xiaoxia Sun; Jay Ahn; Milena A Barcelos; Vanessa N Bezerra; Natalia M Lyra E Silva; Jason Patel; Nathalia R Pinheiro; Lei A Qin; Josette M Kamel; Anthea Weng; Nadia DiNunno; Adrian M Bebenek; Pauline T Velasco; Kirsten L Viola; Pascale N Lacor; Sergio T Ferreira; William L Klein
Journal:  J Neurochem       Date:  2017-08-02       Impact factor: 5.372

Review 9.  Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer's Disease.

Authors:  Zhi-Ting Sun; Chi Ma; Guang-Jian Li; Xiang-Yu Zheng; Yi-Tong Hao; Yu Yang; Xu Wang
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

10.  Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations.

Authors:  Huilai Tian; Eliot Davidowitz; Patricia Lopez; Sharareh Emadi; James Moe; Michael Sierks
Journal:  Int J Cell Biol       Date:  2013-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.